340B Manufacturer Exclusions Summary

Updated May 23, 2023

ManufacturerEffective DateCEs AffectedESP Submissions
Eli Lilly9/1/2020AllYes
AstraZeneca10/1/2020AllNo
Novartis11/16/2020Hospitals OnlyYes
Novo Nordisk1/1/2021Hospitals OnlyYes
Sanofi3/1/2021Hospitals and CHCYes – but HOSPITALS can only pick 1 contract pharmacy starting 6/1/2023
Boehringer Ingelheim8/1/2021Hospitals and CHCNo
Merck9/1/2021Hospitals and CHCYes – but can only pick 1 contract pharmacy starting 6/12/2023
United Therapeutics12/1/2021AllYes
UCB12/31/2021Hospitals OnlyNo
Amgen1/3/2022Hospitals OnlyYes – but can only pick 1 contract pharmacy starting 4/11/2023
Abbvie2/1/2022Hospitals OnlyYes
Bristol Myers Squibb3/1/2022AllNo
Pfizer3/1/2022Hospitals OnlyYes – but can only pick 1 contract pharmacy starting 5/1/2023 specifically for Xeljanz
GlaxoSmithKline4/1/2022Hospitals OnlyYes
Janssen5/2/2022Hospital OnlyYes – but can only pick 1 contract pharmacy starting 3/7/2023
Gilead5/2/2022AllYes
Exelixis7/6/2022Hospitals OnlyYes – but can only pick 1 contract pharmacy starting 5/15/2023
Bausch Health8/1/2022AllYes
Biogen2/1/2023Hospitals OnlyNo
Bayer Health3/1/2023Hospital OnlyYes – but can only pick 1 contract pharmacy starting 6/1/2023
EMD Serono3/1/2023Hospitals OnlyYes

Read the new 2023 Revenue Intelligence™ Data and Insights Report to discover data-backed insights that improve RCM processes.

X